Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

BioNTech Gains On Project Malaria Launch With Eye On Africa Vaccine

Published 07/26/2021, 11:44 AM
Updated 07/26/2021, 11:45 AM
© Reuters

© Reuters

By Dhirendra Tripathi

Investing.com – BioNTech (NASDAQ:BNTX) stock rose more than 3% Monday following the launch of the company’s ‘Project Malaria’ which aims to develop a vaccine to prevent malaria in Africa.

The vaccine will be developed on the company’s mRNA platform, the basis for its highly successful Covid-19 vaccine.

BioNTech will assess multiple vaccine candidates featuring known malaria targets such as the circumsporozoite protein, as well as new antigens discovered in the pre-clinical research phase.

The most promising mRNA vaccine candidates will be selected for clinical development. The start of the clinical trial for the first vaccine candidate is planned for the end of 2022.

The second objective of the company is to develop sustainable vaccine production and supply solutions on the African continent. BioNTech is exploring possibilities to set up state-of-the-art mRNA manufacturing facilities, either with partners or on its own, a note by the company said.

The German company is also working on developing vaccines against dreaded diseases like AIDS and tuberculosis.

According to the WHO, there were an estimated 229 million cases of malaria worldwide in 2019, with 409,000 estimated to have died.

 

 

 

Latest comments

what an Innovative Methodology
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.